Uterine Fibroids: Clinical Manifestations and Contemporary Management. (September 2014)

• Record Type: Journal Article
• Authors: Doherty, Leo; Mutlu, Levent; Sinclair, Donna; Taylor, Hugh
• Is Part Of: Reproductive sciences. Volume 21:Number 9(2014:Sep.)
• Page Start: 1067
• Page End: 1092
• Publication Date: 2014-09
• Subjects: leiomyoma -- female infertility -- growth factors -- implantation; Reproductive health -- Periodicals; Reproduction -- Periodicals; 612.6
• DOI: 10.1177/1933719114533728
• Languages: English
• ISSNs: 1933-7191

Abstract

Uterine fibroids (leiomyomata) are extremely common lesions that are associated with detrimental effects including infertility and abnormal uterine bleeding. Fibroids cause molecular changes at the level of endometrium. Abnormal regulation of growth factors and cytokines in fibroid cells may contribute to negative endometrial effects. Understanding of fibroid biology has greatly increased over the last decade. Although the current armamentarium of Food and Drug Administration-approved medical therapies is limited, there are medications approved for use in heavy menstrual bleeding that can be used for the medical management of fibroids. Emergence of the role of growth factors in pathophysiology of fibroids has led researchers to develop novel therapeutics. Despite advances in medical therapies, surgical management remains a mainstay of fibroid treatment. Destruction of fibroids by interventional radiological procedures provides other effective treatments. Further experimental studies and clinical trials are required to determine which therapies will provide the greatest benefits to patients with fibroids.